Brief: Protara Therapeutics Announces Alignment With FDA On Registrational Path Forward For IV Choline Chloride
05/04/2024 13:09
April 5 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS ANNOUNCES ALIGNMENT WITH FDA ON
REGISTRATIONAL PATH FORWARD FOR IV CHOLINE CHLORIDE IN PATIENTS
DEPENDENT ON PARENTERAL NUTRITION
* PROTARA THERAPEUTICS INC: EXPECTS TO START REGISTRATIONAL
TRIAL
TO SUPPORT FDA APPROVAL OF IV CHOLINE CHLORIDE FOR PN PATIENTS
IN FIRST HALF OF 2025
Source text for Eikon: ID:nGNXl3Q8n
Further company coverage: TARA.O
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses